Skip to content

Tegaserod

Serotonin-4 Receptor Agonist — ALIMENTARY TRACT AND METABOLISM

Also known as: HTF 919, tegaserod maleate, zelnorm

OfmFDA approvedATC A06AX06

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Tegaserod is an ofm drug in the Serotonin-4 Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2002. Its mechanism of action is classified as Serotonin 4 Receptor Agonists. DrugCentral lists 23 molecular targets, including HTR4, HTR2B and HTR4. Recorded indications include Chronic idiopathic constipation and Irritable bowel syndrome characterized by constipation.

  • Approval status: ofm (first approved 2002 by the FDA).
  • Drug class: Serotonin-4 Receptor Agonist.
  • Mechanism of action: Serotonin 4 Receptor Agonists.
  • Molecular targets: HTR4, HTR2B, HTR4 and HTR1D (23 listed in DrugCentral).
  • Indications: Chronic idiopathic constipation and Irritable bowel syndrome characterized by constipation.
  • ATC code: A06AX06 (Other drugs for constipation).
  • Molecular formula: C16H23N5O; molecular weight 301.39 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

  • Chronic idiopathic constipation
  • Irritable bowel syndrome characterized by constipation

Contraindications (14)

  • Acute nephropathy
  • Adhesion of Gastrointestinal Tract
  • Angina pectoris
  • Breastfeeding (mother)
  • Cerebrovascular accident
  • Dehydration
  • Diarrhea
  • Disease of liver
  • Disorder of biliary tract
  • Disorder of gallbladder
  • Hypovolemia
  • Intestinal obstruction
  • Ischemic colitis
  • Myocardial infarction

Mechanism & targets

Mechanism of action (MoA)Serotonin 4 Receptor Agonists
Established pharmacologic classSerotonin-4 Receptor Agonist

Molecular targets (23)

TargetGeneActionActivity
5-hydroxytryptamine receptor 4HTR4partial agonistKi 8.40
5-hydroxytryptamine receptor 2BHTR2BantagonistKi 8.40
5-hydroxytryptamine receptor 4HTR4unknownEC50 7.90
5-hydroxytryptamine receptor 1DHTR1DunknownKi 7.30
Transmembrane protein 97TMEM97unknownKi 7.24
5-hydroxytryptamine receptor 1AHTR1AunknownKi 7.08
5-hydroxytryptamine receptor 2CHTR2CunknownKi 6.85
Sigma non-opioid intracellular receptor 1SIGMAR1unknownKi 6.75
D(4) dopamine receptorDRD4unknownKi 6.72
5-hydroxytryptamine receptor 5AHTR5AunknownKi 6.70
D(2) dopamine receptorDRD2unknownKi 6.53
D(3) dopamine receptorDRD3unknownKi 6.37
5-hydroxytryptamine receptor 2AHTR2AunknownKi 6.37
5-hydroxytryptamine receptor 6HTR6unknownKi 6.25
Alpha-1D adrenergic receptorADRA1DunknownKi 5.79
Alpha-1A adrenergic receptorADRA1AunknownKi 5.79
5-hydroxytryptamine receptor 3AHTR3AunknownKi 5.60
Alpha-1B adrenergic receptorADRA1BunknownKi 5.58
Mu-type opioid receptorOPRM1unknownKi 5.55
Alpha-2B adrenergic receptorADRA2BunknownKi 5.55

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2002-07-24FDA——

ATC classification

ATC codeTherapeutic hierarchy
A06AX06ALIMENTARY TRACT AND METABOLISM › DRUGS FOR CONSTIPATION › DRUGS FOR CONSTIPATION › Other drugs for constipation

Chemical structure

Molecular formulaC16H23N5O
Molecular weight301.39 g/mol
CAS number—
InChIKeyIKBKZGMPCYNSLU-UHFFFAOYSA-N
PubChem CID135409453
CCCCCNC(=N)NN=CC1=CNC2=C1C=C(OC)C=C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Tegaserod used for?

DrugCentral lists the following indications for Tegaserod: Chronic idiopathic constipation and Irritable bowel syndrome characterized by constipation.

How does Tegaserod work?

Tegaserod is classified as Serotonin 4 Receptor Agonists; its molecular targets in DrugCentral include HTR4 (partial agonist), HTR2B (antagonist), HTR4 and HTR1D.

When was Tegaserod first approved?

Tegaserod was first approved by the FDA in 2002.

What drug class does Tegaserod belong to?

Tegaserod is in the Serotonin-4 Receptor Agonist class.

What is the chemical formula of Tegaserod?

Tegaserod has the molecular formula C16H23N5O and a molecular weight of 301.39 g/mol.

Browse: all drugs starting with T · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFM
First approval2002-07-24
AgencyFDA
Targets23
Indications2
FormulaC16H23N5O
DrugCentral ID2579
Interactive profile